Oncology Nursing Exam Prep 2026/2027 | 70
OCN Practice Questions with Evidence-
Based Rationales | Cancer Care Certification
Study Guide
Description:
Master oncology nursing for 2026/2027 with 70 exam-style questions covering chemotherapy,
pain management, oncologic emergencies, and survivorship care. Each answer includes
detailed, evidence-based rationales aligned with NCCN guidelines.
Download Your Complete Oncology Nursing Exam Bank Now and Ace Your 2026/2027
Certification!
, Oncology Nursing Exam 2026/2027: 70 Questions & Answers
Question 1
A nurse educator is presenting a lecture on cancer biology. Which statement accurately describes
the role of a proto-oncogene in normal cellular function?
A. Initiates the process of angiogenesis in healthy tissues
B. Triggers programmed cell death when cellular damage occurs
C. Suppresses abnormal cellular proliferation through regulatory mechanisms
D. Promotes cellular differentiation and controlled division in normal cells
Answer: D. Promotes cellular differentiation and controlled division in normal cells
Explanation: Proto-oncogenes are normal cellular genes that regulate cell growth,
differentiation, and division. When these genes undergo mutation or are expressed at abnormally
high levels, they can become oncogenes that contribute to malignant transformation. The three
primary mechanisms by which proto-oncogenes convert to oncogenes include point mutations
(alteration of a single nucleotide base pair), chromosomal translocations (where a chromosomal
segment breaks off and reattaches to a different chromosome), and gene amplification (increased
copies of the proto-oncogene). Understanding this fundamental concept is essential for oncology
nurses as it underpins targeted therapy development and personalized cancer treatment
approaches.
Question 2
Which terminology correctly identifies malignancies that originate in epithelial tissue?
A. Osteosarcoma and chondrosarcoma
B. Lymphoma and myeloma
C. Adenocarcinoma and squamous cell carcinoma
D. Liposarcoma and rhabdomyosarcoma
Answer: C. Adenocarcinoma and squamous cell carcinoma
Explanation: Tumors are classified according to their tissue of origin, which determines their
nomenclature. Malignancies arising from epithelial tissue include adenocarcinomas (glandular
epithelium), squamous cell carcinomas (squamous epithelium), basal cell carcinomas, and
choriocarcinomas. Neoplasms of mesenchymal origin are termed sarcomas, with specific
prefixes indicating the tissue type: osteo- (bone), chondro- (cartilage), lipo- (fat), and rhabdo-
,(striated muscle). Hematopoietic malignancies include lymphomas (lymphoid tissue) and
leukemias (blood-forming tissues). Accurate histopathological classification is essential for
determining treatment protocols and predicting clinical outcomes.
Question 3
A patient diagnosed with chronic leukemia is being evaluated for new-onset tachycardia and
dyspnea. Which laboratory finding most likely explains these symptoms?
A. Hemoglobin level of 7.8 g/dL
B. Platelet count of 1,000,000/mm³
C. White blood cell count of 2,960/mm³
D. Absolute neutrophil count of 1,700/mm³
Answer: A. Hemoglobin level of 7.8 g/dL
Explanation: Anemia is characterized by reduced hemoglobin concentration or red blood cell
mass. Severe anemia, defined as hemoglobin below 8 g/dL, manifests clinically with tachycardia,
exertional dyspnea, angina, headache, dizziness, and fatigue. These symptoms result from
diminished oxygen-carrying capacity and compensatory cardiovascular responses. While
thrombocytosis (elevated platelets), leukopenia (low white blood cells), and neutropenia (low
absolute neutrophil count) are clinically significant findings in hematologic malignancies, they
do not directly explain the patient's cardiorespiratory symptoms. Oncology nurses must
recognize anemia's clinical presentation and understand its pathophysiological basis to
implement appropriate interventions and monitoring protocols.
Question 4
A 68-year-old patient with CD33-positive acute myeloid leukemia in first relapse has a left
ventricular ejection fraction of 38%. Which therapeutic agent would the oncology nurse
anticipate being prescribed?
A. Gemtuzumab ozogamicin
B. All-trans retinoic acid
C. High-dose cytarabine
D. Rituximab
Answer: A. Gemtuzumab ozogamicin
Explanation: Gemtuzumab ozogamicin is an antibody-drug conjugate indicated for the
, treatment of relapsed CD33-positive acute myeloid leukemia in patients aged 60 years or older
who are not candidates for intensive cytotoxic chemotherapy. This targeted therapy consists of a
humanized monoclonal antibody directed against CD33, conjugated to the potent cytotoxic agent
calicheamicin. The reduced cardiac function (ejection fraction of 38%) in this patient precludes
the use of cardiotoxic agents such as anthracyclines. All-trans retinoic acid is primarily used for
acute promyelocytic leukemia, while rituximab targets CD20-positive B-cell malignancies.
Understanding targeted therapy indications is crucial for oncology nurses managing complex
hematologic malignancies.
Question 5
A patient with newly diagnosed non-small cell lung cancer has significantly impaired pulmonary
function. Given these clinical circumstances, which treatment modality is most appropriate?
A. Platinum-based combination chemotherapy
B. Curative-intent external beam radiation therapy
C. Lobectomy with mediastinal lymph node dissection
D. Pneumonectomy with adjuvant therapy
Answer: B. Curative-intent external beam radiation therapy
Explanation: Patients with early-stage non-small cell lung cancer who are medically inoperable
due to compromised pulmonary function or significant comorbidities may be candidates for
definitive radiation therapy. Stereotactic body radiation therapy (SBRT) or conventional external
beam radiation can achieve curative outcomes in carefully selected patients with stage I or II
disease. Surgical resection (lobectomy or pneumonectomy) remains the standard of care for
operable patients but carries significant morbidity and mortality risks in those with impaired
pulmonary reserve. While chemotherapy may be incorporated in multimodal approaches,
radiation therapy offers a potentially curative, less invasive option for this patient population.
Oncology nurses must understand treatment selection criteria to provide comprehensive patient
education and support.
OCN Practice Questions with Evidence-
Based Rationales | Cancer Care Certification
Study Guide
Description:
Master oncology nursing for 2026/2027 with 70 exam-style questions covering chemotherapy,
pain management, oncologic emergencies, and survivorship care. Each answer includes
detailed, evidence-based rationales aligned with NCCN guidelines.
Download Your Complete Oncology Nursing Exam Bank Now and Ace Your 2026/2027
Certification!
, Oncology Nursing Exam 2026/2027: 70 Questions & Answers
Question 1
A nurse educator is presenting a lecture on cancer biology. Which statement accurately describes
the role of a proto-oncogene in normal cellular function?
A. Initiates the process of angiogenesis in healthy tissues
B. Triggers programmed cell death when cellular damage occurs
C. Suppresses abnormal cellular proliferation through regulatory mechanisms
D. Promotes cellular differentiation and controlled division in normal cells
Answer: D. Promotes cellular differentiation and controlled division in normal cells
Explanation: Proto-oncogenes are normal cellular genes that regulate cell growth,
differentiation, and division. When these genes undergo mutation or are expressed at abnormally
high levels, they can become oncogenes that contribute to malignant transformation. The three
primary mechanisms by which proto-oncogenes convert to oncogenes include point mutations
(alteration of a single nucleotide base pair), chromosomal translocations (where a chromosomal
segment breaks off and reattaches to a different chromosome), and gene amplification (increased
copies of the proto-oncogene). Understanding this fundamental concept is essential for oncology
nurses as it underpins targeted therapy development and personalized cancer treatment
approaches.
Question 2
Which terminology correctly identifies malignancies that originate in epithelial tissue?
A. Osteosarcoma and chondrosarcoma
B. Lymphoma and myeloma
C. Adenocarcinoma and squamous cell carcinoma
D. Liposarcoma and rhabdomyosarcoma
Answer: C. Adenocarcinoma and squamous cell carcinoma
Explanation: Tumors are classified according to their tissue of origin, which determines their
nomenclature. Malignancies arising from epithelial tissue include adenocarcinomas (glandular
epithelium), squamous cell carcinomas (squamous epithelium), basal cell carcinomas, and
choriocarcinomas. Neoplasms of mesenchymal origin are termed sarcomas, with specific
prefixes indicating the tissue type: osteo- (bone), chondro- (cartilage), lipo- (fat), and rhabdo-
,(striated muscle). Hematopoietic malignancies include lymphomas (lymphoid tissue) and
leukemias (blood-forming tissues). Accurate histopathological classification is essential for
determining treatment protocols and predicting clinical outcomes.
Question 3
A patient diagnosed with chronic leukemia is being evaluated for new-onset tachycardia and
dyspnea. Which laboratory finding most likely explains these symptoms?
A. Hemoglobin level of 7.8 g/dL
B. Platelet count of 1,000,000/mm³
C. White blood cell count of 2,960/mm³
D. Absolute neutrophil count of 1,700/mm³
Answer: A. Hemoglobin level of 7.8 g/dL
Explanation: Anemia is characterized by reduced hemoglobin concentration or red blood cell
mass. Severe anemia, defined as hemoglobin below 8 g/dL, manifests clinically with tachycardia,
exertional dyspnea, angina, headache, dizziness, and fatigue. These symptoms result from
diminished oxygen-carrying capacity and compensatory cardiovascular responses. While
thrombocytosis (elevated platelets), leukopenia (low white blood cells), and neutropenia (low
absolute neutrophil count) are clinically significant findings in hematologic malignancies, they
do not directly explain the patient's cardiorespiratory symptoms. Oncology nurses must
recognize anemia's clinical presentation and understand its pathophysiological basis to
implement appropriate interventions and monitoring protocols.
Question 4
A 68-year-old patient with CD33-positive acute myeloid leukemia in first relapse has a left
ventricular ejection fraction of 38%. Which therapeutic agent would the oncology nurse
anticipate being prescribed?
A. Gemtuzumab ozogamicin
B. All-trans retinoic acid
C. High-dose cytarabine
D. Rituximab
Answer: A. Gemtuzumab ozogamicin
Explanation: Gemtuzumab ozogamicin is an antibody-drug conjugate indicated for the
, treatment of relapsed CD33-positive acute myeloid leukemia in patients aged 60 years or older
who are not candidates for intensive cytotoxic chemotherapy. This targeted therapy consists of a
humanized monoclonal antibody directed against CD33, conjugated to the potent cytotoxic agent
calicheamicin. The reduced cardiac function (ejection fraction of 38%) in this patient precludes
the use of cardiotoxic agents such as anthracyclines. All-trans retinoic acid is primarily used for
acute promyelocytic leukemia, while rituximab targets CD20-positive B-cell malignancies.
Understanding targeted therapy indications is crucial for oncology nurses managing complex
hematologic malignancies.
Question 5
A patient with newly diagnosed non-small cell lung cancer has significantly impaired pulmonary
function. Given these clinical circumstances, which treatment modality is most appropriate?
A. Platinum-based combination chemotherapy
B. Curative-intent external beam radiation therapy
C. Lobectomy with mediastinal lymph node dissection
D. Pneumonectomy with adjuvant therapy
Answer: B. Curative-intent external beam radiation therapy
Explanation: Patients with early-stage non-small cell lung cancer who are medically inoperable
due to compromised pulmonary function or significant comorbidities may be candidates for
definitive radiation therapy. Stereotactic body radiation therapy (SBRT) or conventional external
beam radiation can achieve curative outcomes in carefully selected patients with stage I or II
disease. Surgical resection (lobectomy or pneumonectomy) remains the standard of care for
operable patients but carries significant morbidity and mortality risks in those with impaired
pulmonary reserve. While chemotherapy may be incorporated in multimodal approaches,
radiation therapy offers a potentially curative, less invasive option for this patient population.
Oncology nurses must understand treatment selection criteria to provide comprehensive patient
education and support.
